Given the association between MCC and immune status, various immune checkpoint inhibitors including the programmed cell death ligand 1 inhibitor drug avelumab and the anti–programmed cell death 1 drugs nivolumab and pembrolizumab have been investigated in metastatic MCC. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.